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Abstract 14 
Background: Respiratory disease is a common co-morbidity with rheumatoid arthritis 15 
(RA). RA commonly affects the hands, but there is little research investigating 16 
whether these patients are physically able to operate inhalers. 17 
Aim: To compare the physical ability of people with and without RA to use four 18 
commonly prescribed inhaler devices (pressurised metered dose inhaler (pMDI), 19 
Easi-Breathe®, HandiHaler® and Turbohaler®). 20 
Methods: Adults with RA and an equal number of age-sex matched controls were 21 
observed using placebo inhaler devices. Maximum inhalation flow rate was 22 
measured with an In-Check Dial device. Dichotomous data were compared (RA 23 
versus control) using Fisher’s exact test. 24 
Results: Thirty four participants were recruited for each group. For all inhalers, fewer 25 
participants with RA were able to complete all the steps necessary to operate the 26 
device: pMDI (50% vs. 91%), Easi-Breathe® (77% vs. 97%), HandiHaler® (15% vs. 27 
94%) and Turbohaler® (85% vs. 100%). This difference was significant (p<0.05) for 28 
the pMDI, Easi-Breathe® and HandiHaler®. Significantly fewer people (p<0.05) with 29 
RA were able to depress the pMDI canister, or to complete three steps in the 30 
operation of the Handihaler® (open the dust cap, remove the capsule from its blister, 31 
pierce the capsule). Only one participant (RA group) was unable to achieve the 32 
minimum flow rates required to operate the Turbohaler® and HandiHaler® 33 
(p=1.000). 34 
Conclusions: People with RA have varying physical abilities to use inhalers 35 
effectively. A person-centred approach is required to assess which inhaler device is 36 
appropriate for each individual patient. 37 
 38 
KEYWORDS: Arthritis, Rheumatoid; Dry Powder Inhalers; Human Engineering; 39 
Metered Dose Inhalers; Nebulizers and Vaporizers  40 
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Introduction 41 
Respiratory diseases are common in people with rheumatoid arthritis (RA), with up to 42 
21% of people with RA having asthma and up to 8% having chronic obstructive 43 
pulmonary disease [1]. These people are likely to need to use inhalers. 44 
Up to 70% of people with RA develop hand disability [2], and lung complications are 45 
a common extra-articular manifestation of RA [3]. Correct use of an inhaler requires 46 
both manipulation of the device and an appropriate inhalation manoeuvre, leading to 47 
anecdotal reports that people with RA have difficulty with these techniques [4-7]. 48 
However, to date only one study has investigated the usability of inhaler devices in 49 
people with RA [8]. This found significantly lower (though satisfactory) participant-50 
reported ease-of-use of the Genuair® device for people with hand arthritis. 51 
This study compared the physical ability of people with and without RA to use 52 
commonly prescribed inhaler devices [9]. Devices that are representative of larger 53 
classes of device were selected: pressurised metered dose inhaler (pMDI, QVAR® 54 
brand), breath-actuated pMDI (Easi-Breathe®), HandiHaler® (capsule dry powder 55 
inhaler) and Turbohaler® (multi-dose dry powder inhaler). 56 
The pMDI and Easi-Breathe® are low resistance devices and require a slow 57 
inhalation, so have no minimum inhalation flow requirement [10]. However, the 58 
Turbohaler® and HandiHaler® are higher resistance devices and require a minimum 59 
inhalation rate for effective drug delivery: >30 L.min-1 and >20 L.min-1, respectively 60 
[10]. Therefore, the ability of participants to achieve these flow rates was also 61 
investigated. 62 
 63 
Participants and Methods 64 
An observational study was performed with age-sex matched pairs of participants 65 
with and without RA. Adults (>18 years) with physician-diagnosed RA were recruited 66 
at National Rheumatoid Arthritis Society support group meetings. Age (±2 years) and 67 
sex matched controls were recruited via the researchers’ networks. Participants gave 68 
written informed consent before participation in an individual data collection session. 69 
Page 4 of 11 
 
Participants with RA completed the Health Assessment Questionnaire Disability 70 
Index (HAQ-DI), a widely used and psychometrically validated tool which measures 71 
functional ability in daily life in people with RA [11]. HAQ-DI scores were calculated 72 
using the standard method, giving values between 0 (no disability) and 3 (very 73 
severe disability) [11]. All participants completed the first two scales of the Michigan 74 
Hand Outcomes Questionnaire (MHQ), a psychometrically validated tool which 75 
assesses hand function [12]. MHQ scores were calculated following the method 76 
described by Chung et al., giving values between 0 (minimum hand function) and 77 
100 (perfect hand function) [12]. 78 
Steps for the operation of each inhaler device were determined from the Patient 79 
Information Leaflet. Using placebo devices, a researcher demonstrated each step 80 
and then observed the participant’s ability to perform the same manipulation. 81 
Participants did not perform an inhalation via the placebo devices. Instead, an In-82 
Check Dial 6 device (Clement Clarke International, Harlow, UK) set to Turbohaler® 83 
resistance was used to record participants’ maximum inhalation flow rate [13]. 84 
Participants performed one practice inhalation, followed by three measurements of 85 
which the highest was recorded. The flow rate that each participant could have 86 
achieved via a HandiHaler® (a higher resistance device than the Turbohaler®) was 87 
calculated using the following relationship [14] and the resistances of the 88 
HandiHaler® and Turbohaler® (0.158 and 0.120 (cm H2O)0.5.L.min-1, respectively) 89 
[15] 90 
√𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝐷𝑟𝑜𝑝 𝐴𝑐𝑟𝑜𝑠𝑠 𝐼𝑛ℎ𝑎𝑙𝑒𝑟 =  𝐼𝑛ℎ𝑎𝑙𝑒𝑟 𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 × 𝐼𝑛ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝐹𝑙𝑜𝑤 𝑅𝑎𝑡𝑒 91 
The In-Check Dial 6 device has considerable handling differences compared with the 92 
four inhaler devices. However, these differences were not relevant, as the In-Check 93 
Dial 6 device was only used to measure respiratory function (maximum inhalation 94 
flow rate), not the physical ability to manipulate inhaler devices. 95 
Data were analysed using SPSS Statistics 22 (IBM Corp., Armonk, NY, USA). 96 
Dichotomous data were compared (RA versus control) using Fisher’s exact test. 97 
MHQ scores were compared using the Mann-Whitney U-test. In all cases, a 98 
significance level of 5% was used. To have 90% power to detect a difference 99 
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between 100% of controls and 75% of people with RA being able to use an inhaler, 100 
each group required 32 participants. 101 
The study was approved by the University of Bath Ethical Implications of Research 102 
Activity process. 103 
  104 
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Results and Discussion 105 
Results and participants’ demographic details are summarised in Table 1.  106 
Table 1: demographic details and physical ability to use inhaler devices of 107 









Percentage of females (n) 76% (26)  76% (26)  
    
Age range (years) 31 – 86  31 – 85  
Mean age (years ± SD) 60.8 ± 13.0 60.8 ± 13.2  
    
Percentage with respiratory co-morbidity (n) 38% (13) 12% (4) 0.023 
    
HAQ-DI score range 0.125 – 3.0 -  
Mean HAQ-DI score ± SD 1.58 ± 0.68 -  
    
Median MHQ score (range) 54.9 (6.8 – 96.0) 100.0 (57.5 – 100.0) <0.001 
    
Pressurised metered dose inhaler – percentage (n) of participants who… 
…had previously used device 44% (15) 18% (6) 0.034 
…could complete all steps 50% (17) 91% (31) <0.001 
…could remove cap 100% (34) 100% (34) - 
...could shake device 97% (33) 100% (34) 1.000 
...could depress canister 53% (18) 91% (31) <0.001 
...could replace cap 100% (34) 100% (34) - 
    
Easi-Breathe® inhaler – percentage (n) of participants who… 
…had previously used device 18% (6) 6% (2) 0.259 
…could complete all steps 77% (26) 97% (33) 0.027 
...could shake device 100% (34) 100% (34) - 
...could fold down cap 91% (31) 97% (33) 0.239 
...could close cap 85% (29) 100% (34) 0.197 
    
HandiHaler® – percentage (n) of participants who… 
…had previously used device 18% (6) 3% (1) 0.105 
…could complete all steps 15% (5) 94% (32) <0.001 
... could open dust cap 79% (27) 100% (34) 0.011 
... could open mouthpiece 85% (29) 100% (34) 0.053 
... could remove capsule from blister 65% (22) 94% (32) 0.006 
... could close mouthpiece 100% (34) 100% (34) - 
... could pierce capsule 21% (7) 94% (32) <0.001 
... could remove capsule 91% (31) 100% (34) 0.239 
... could close mouthpiece and dust cap 100% (34) 100% (34) - 
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Turbohaler® – percentage (n) of participants who… 
…had previously used device 6% (2) 0% (0) 0.493 
… could complete all steps 85% (29) 100% (34) 0.053 
... could unscrew cap 97% (33) 100% (34) 1.000 
... could twist grip to activate 88% (30) 100% (34) 0.114 
.. could replace cap 100% (34) 100% (34) - 
    
Percentage (n) of participants with inhalation flow rate… 
…>30 L.min-1 (measured) with Turbohaler® 
resistance (%) 
97% (33) 100% (34) 1.000 
…>20 L.min-1 (calculated) with HandiHaler® 
resistance (%) 
97% (33) 100% (34) 1.000 
 109 
The HAQ-DI scores obtained from the RA group indicated mild through to very 110 
severe disability [11]. The MHQ scores of the RA group were significantly lower than 111 
the control group, demonstrating poorer hand function in people with RA [12]. These 112 
results suggest that representative participants were recruited. 113 
For all inhalers, a smaller proportion of the RA group was able to complete all the 114 
necessary steps. This difference was statistically significant for the pMDI, Easi-115 
Breathe® and HandiHaler®, despite significantly more of the RA group having 116 
previous experience of pMDI use. 117 
The pMDI step which caused the most difficulty was depressing the canister. This 118 
applied to both groups, although the RA group were significantly less likely to 119 
complete this step. Similar results to the control group have been reported before for 120 
older people without RA [16]. This may be as a result of the force required to 121 
depress a pMDI canister [4]. 122 
For the HandiHaler® three steps caused significantly more difficulty for the RA 123 
group: opening the dust cap, removing the capsule from its blister, and piercing the 124 
capsule. The latter two steps are similar in other capsule inhaler designs, suggesting 125 
this whole class of devices might be unsuitable for people with RA. 126 
Only one participant (RA group) was unable to achieve the minimum inhalation rates 127 
required to operate the Turbohaler® and HandiHaler®, and this participant was also 128 
unable to perform all the necessary manipulations to use either of these devices. 129 
Despite a significantly greater proportion of the RA group having a respiratory co-130 
morbidity, there was no significant difference between the number of participants in 131 
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each group able to achieve the minimum inhalation rates. This suggests that lung 132 
manifestations of RA are not important in determining whether people are able to 133 
use an inhaler appropriately. 134 
With time, people with RA might develop strategies to enable them to use an inhaler. 135 
However, these results were obtained despite more participants in the RA group 136 
having prior experience with each inhaler device (significantly more for the pMDI), 137 
suggesting that these findings can be extrapolated to long-term use in people with 138 
RA and respiratory disease. In addition, the participants enrolled in this study were 139 
directly representative of people with RA beginning to use a new type of inhaler. 140 
These results are therefore especially applicable to the initiation of adherence to an 141 
inhaled medicine, which is known to be poor in many patients [17]. 142 
 143 
Limitations 144 
A large number of inhaler devices are available, so the small range used in this study 145 
is a limitation. However, the devices studied are commonly prescribed [9] and 146 
representative of larger classes. Lack of observation validation is another limitation, 147 
however the ability to perform every inhaler step could be determined objectively. 148 
 149 
Conclusions 150 
This is the first study comparing the physical ability of people to RA to use different 151 
inhaler devices. It demonstrates the varying physical abilities of people with RA to 152 
use inhalers effectively. Therefore, a person-centred approach is required to assess 153 
which inhaler device is appropriate for each individual patient [18, 19]. 154 
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